The pharmaceutical industry must not offer cash or other financial incentives to pharmacies, physicians or benefit managers to switch a patient’s prescription from one manufacturer’s drug to a rival product, the US government warned on Monday.
Such inducements may be viewed as “kickbacks” prohibited under federal law, according to draft compliance guidelines issued by the Health and Human Services Office of Inspector General (OIG).
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!